KYORIN Pharmaceutical Co., Ltd. 4569.T Stock
KYORIN Pharmaceutical Co., Ltd. Price Chart
KYORIN Pharmaceutical Co., Ltd. 4569.T Financial and Trading Overview
KYORIN Pharmaceutical Co., Ltd. stock price | 1812 JPY |
Previous Close | 1741 JPY |
Open | 1738 JPY |
Bid | 1754 JPY x 0 |
Ask | 1759 JPY x 0 |
Day's Range | 1737 - 1759 JPY |
52 Week Range | 1639 - 1897 JPY |
Volume | 202.7K JPY |
Avg. Volume | 85.27K JPY |
Market Cap | 100.68B JPY |
Beta (5Y Monthly) | -0.056704 |
PE Ratio (TTM) | 17.20188 |
EPS (TTM) | 74.32 JPY |
Forward Dividend & Yield | 64 (3.67%) |
Ex-Dividend Date | September 28, 2023 |
1y Target Est | 1750 JPY |
4569.T Valuation Measures
Enterprise Value | 101.48B JPY |
Trailing P/E | 17.20188 |
Forward P/E | 20.682755 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 0.88884467 |
Price/Book (mrq) | 0.8025099 |
Enterprise Value/Revenue | 0.896 |
Enterprise Value/EBITDA | 11.324 |
Trading Information
KYORIN Pharmaceutical Co., Ltd. Stock Price History
Beta (5Y Monthly) | -0.056704 |
52-Week Change | 4.75% |
S&P500 52-Week Change | 20.43% |
52 Week High | 1897 JPY |
52 Week Low | 1639 JPY |
50-Day Moving Average | 1740.8 JPY |
200-Day Moving Average | 1739.68 JPY |
4569.T Share Statistics
Avg. Volume (3 month) | 85.27K JPY |
Avg. Daily Volume (10-Days) | 111.58K JPY |
Shares Outstanding | 57.3M |
Float | 39.41M |
Short Ratio | N/A |
% Held by Insiders | 33.43% |
% Held by Institutions | 17.98% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 52 |
Trailing Annual Dividend Yield | 2.98% |
5 Year Average Dividend Yield | 344.00% |
Payout Ratio | 0.5114 |
Last Split Factor | 15:10 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | March 31, 2023 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | March 31, 2024 |
Profitability
Profit Margin | 4.16% |
Operating Margin (ttm) | 4.52% |
Gross Margin | 44.29% |
EBITDA Margin | 7.91% |
Management Effectiveness
Return on Assets (ttm) | 1.83% |
Return on Equity (ttm) | 3.77% |
Income Statement
Revenue (ttm) | 113.27B JPY |
Revenue Per Share (ttm) | 1976.68 JPY |
Quarterly Revenue Growth (yoy) | 17.10% |
Gross Profit (ttm) | N/A |
EBITDA | 8.96B JPY |
Net Income Avi to Common (ttm) | 4.72B JPY |
Diluted EPS (ttm) | 102.14 |
Quarterly Earnings Growth (yoy) | -76.099% |
Balance Sheet
Total Cash (mrq) | 19.39B JPY |
Total Cash Per Share (mrq) | 338.44 JPY |
Total Debt (mrq) | 21.28B JPY |
Total Debt/Equity (mrq) | 16.96 JPY |
Current Ratio (mrq) | 3.403 |
Book Value Per Share (mrq) | 2189.381 |
Cash Flow Statement
Operating Cash Flow (ttm) | 2.01B JPY |
Levered Free Cash Flow (ttm) | -10345624576 JPY |
Profile of KYORIN Pharmaceutical Co., Ltd.
Country | Japan |
State | N/A |
City | Tokyo |
Address | 6, Kanda Surugadai 4-Chome |
ZIP | 101-8311 |
Phone | 81 3 3525 4711 |
Website | https://www.kyorin-pharm.co.jp |
Industry | Drug Manufacturers-Specialty & Generic |
Sector(s) | Healthcare |
Full Time Employees | N/A |
KYORIN Pharmaceutical Co., Ltd., through its subsidiaries, researches and develops, manufactures, and sells ethical and generic drugs in Japan and internationally. The company offers Flutiform, a drug for the treatment of asthma; Lyfuna for cough treatment; Desalex, an antiallergic agent; Beova, Uritos, and Imidafenacin KYORIN therapeutic agents for overactive bladder; Lasvic, a quinolone synthetic antibacterial agent; Pentasa, a remedy for ulcerative colitis/Crohn's disease; Nasonex and Mometasone KYORIN, which are used as allergic rhinitis therapeutic agents; and Kipres, a leukotriene receptor antagonist anti-bronchial asthma and allergic rhinitis drug. It also provides Mucodyne, a mucoregulating drug; Montelukast KM, a drug for the treatment of bronchial asthma and allergic rhinitis; GeneSoC, a real-time PCR system; Rubysta, a disinfectant cleaner; Milton, a disinfectant; over-the-counter drugs; prescription medicines and quasi-drugs, diagnostics, and industrial chemicals; and reagents, intermediates, and other products. In addition, the company offers subcontracted drug manufacturing services. Further, it is involved in the discovery and evaluation of candidate compounds; and research and analysis of other companies' technologies and collection of information concerning clinical trial. The company was formerly known as KYORIN Holdings, Inc. KYORIN Pharmaceutical Co., Ltd. was founded in 1923 and is headquartered in Tokyo, Japan.
Q&A For KYORIN Pharmaceutical Co., Ltd. Stock
What is a current 4569.T stock price?
KYORIN Pharmaceutical Co., Ltd. 4569.T stock price today per share is 1812 JPY.
How to purchase KYORIN Pharmaceutical Co., Ltd. stock?
You can buy 4569.T shares on the Tokyo exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for KYORIN Pharmaceutical Co., Ltd.?
The stock symbol or ticker of KYORIN Pharmaceutical Co., Ltd. is 4569.T.
Which industry does the KYORIN Pharmaceutical Co., Ltd. company belong to?
The KYORIN Pharmaceutical Co., Ltd. industry is Drug Manufacturers-Specialty & Generic.
How many shares does KYORIN Pharmaceutical Co., Ltd. have in circulation?
The max supply of KYORIN Pharmaceutical Co., Ltd. shares is 57.3M.
What is KYORIN Pharmaceutical Co., Ltd. Price to Earnings Ratio (PE Ratio)?
KYORIN Pharmaceutical Co., Ltd. PE Ratio is 24.38105600 now.
What was KYORIN Pharmaceutical Co., Ltd. earnings per share over the trailing 12 months (TTM)?
KYORIN Pharmaceutical Co., Ltd. EPS is 74.32 JPY over the trailing 12 months.
Which sector does the KYORIN Pharmaceutical Co., Ltd. company belong to?
The KYORIN Pharmaceutical Co., Ltd. sector is Healthcare.
KYORIN Pharmaceutical Co., Ltd. 4569.T included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Developed ex US SC NTR G NQDMXUSSCGBPN | 1704.47 GBP 2179.91 USD |
0
|
— — | 1704.47 GBP 2179.91 USD | 1704.47 GBP 2179.91 USD | — - | — — |
- {{ link.label }} {{link}}